JP7598329B2 - 標的分子を修飾するための組成物及び方法 - Google Patents

標的分子を修飾するための組成物及び方法 Download PDF

Info

Publication number
JP7598329B2
JP7598329B2 JP2021556715A JP2021556715A JP7598329B2 JP 7598329 B2 JP7598329 B2 JP 7598329B2 JP 2021556715 A JP2021556715 A JP 2021556715A JP 2021556715 A JP2021556715 A JP 2021556715A JP 7598329 B2 JP7598329 B2 JP 7598329B2
Authority
JP
Japan
Prior art keywords
polypeptide
molecule
cases
target molecule
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527247A5 (https=
JP2022527247A (ja
Inventor
マシュー ビー． フランシス
マルコ ジャクソン ロッバ
ジョナサン チャールズ マザ
アラン エム． マーメルスタイン
ジェニファー エイ． ダウドナ
クリストフ フェルマン
ケイシー エス． モギレフスキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022527247A publication Critical patent/JP2022527247A/ja
Publication of JP2022527247A5 publication Critical patent/JP2022527247A5/ja
Priority to JP2024207936A priority Critical patent/JP2025029024A/ja
Application granted granted Critical
Publication of JP7598329B2 publication Critical patent/JP7598329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2021556715A 2019-03-22 2020-03-19 標的分子を修飾するための組成物及び方法 Active JP7598329B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024207936A JP2025029024A (ja) 2019-03-22 2024-11-29 標的分子を修飾するための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962822616P 2019-03-22 2019-03-22
US62/822,616 2019-03-22
US201962910836P 2019-10-04 2019-10-04
US62/910,836 2019-10-04
PCT/US2020/023634 WO2020197934A1 (en) 2019-03-22 2020-03-19 Compositions and methods for modification of target molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024207936A Division JP2025029024A (ja) 2019-03-22 2024-11-29 標的分子を修飾するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022527247A JP2022527247A (ja) 2022-06-01
JP2022527247A5 JP2022527247A5 (https=) 2023-03-16
JP7598329B2 true JP7598329B2 (ja) 2024-12-11

Family

ID=72611716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556715A Active JP7598329B2 (ja) 2019-03-22 2020-03-19 標的分子を修飾するための組成物及び方法
JP2024207936A Pending JP2025029024A (ja) 2019-03-22 2024-11-29 標的分子を修飾するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024207936A Pending JP2025029024A (ja) 2019-03-22 2024-11-29 標的分子を修飾するための組成物及び方法

Country Status (8)

Country Link
US (2) US20220153779A1 (https=)
EP (1) EP3941927A4 (https=)
JP (2) JP7598329B2 (https=)
KR (1) KR20220003506A (https=)
CN (2) CN113891893A (https=)
AU (1) AU2020247788A1 (https=)
CA (1) CA3134423A1 (https=)
WO (1) WO2020197934A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115244176A (zh) * 2019-08-19 2022-10-25 钟明宏 向导rna-cas蛋白复合物的缀合物
JP2024506608A (ja) 2021-02-08 2024-02-14 エメンドバイオ・インコーポレイテッド Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ
US20240425885A1 (en) * 2021-02-08 2024-12-26 Emendobio Inc. OMNI 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 CRISPR NUCLEASE
EP4347818A2 (en) 2021-06-01 2024-04-10 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
US20230128981A1 (en) * 2021-10-20 2023-04-27 Florida State University Research Foundation, Incorporated Cd24-loaded vesicles for treatment of cytokine storm and other conditions
CN114540325B (zh) * 2022-01-17 2022-12-09 广州医科大学 靶向dna去甲基化的方法、融合蛋白及其应用
CN119731192A (zh) * 2022-10-14 2025-03-28 香港中文大学 免疫球蛋白的位点特异性酪氨酸修饰
WO2024137771A1 (en) * 2022-12-22 2024-06-27 The Regents Of The University Of California Methods and compositions for in situ identification of protein-nucleic acid interaction sites
EP4653020A1 (en) * 2023-01-19 2025-11-26 Shanghai Shengdi Pharmaceutical Co., Ltd Tyrosinase-mediated protein site-specific conjugation and use thereof
KR20250151430A (ko) 2023-02-15 2025-10-21 아버 바이오테크놀로지스, 인크. 스타스민 2(stmn2) 전사체에서 비정상적인 스플라이싱을 억제하는 유전자 편집 방법
TW202519268A (zh) * 2023-09-11 2025-05-16 美商卡蒂那生物科學股份有限公司 多肽結合組合物及使用方法
WO2025129098A1 (en) * 2023-12-14 2025-06-19 Catena Biosciences, Inc. Tyrosinase-based conjugate compositions and methods of use
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
WO2025264834A1 (en) * 2024-06-20 2025-12-26 Arizona Board Of Regents On Behalf Of Arizona State University Dna (rna) assembly mediated by charged and charge-switching peptides
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153250A2 (en) * 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives
AU2013341711A1 (en) * 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
AU2015277100A1 (en) * 2014-06-20 2017-02-02 Abgenomics International Inc. HER2 antibody-drug conjugates
WO2017106937A1 (en) * 2015-12-24 2017-06-29 Monash University Enzymatically active supramolecular assemblies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Tyrosinase from mashroom"，PRODUCT INFORMATION，SIGMA-ALDRICH，T3824，KERTESZ, D., and ZITO, R., BIOCHIM. BIOPHYS. ACTA, 96(3), 447-462 (1965).
ICHITANI, M., et al.，"Spectroscopic characterization of thiol adducts formed in the reaction of 4-methylcatechol with DPPH in the presence of N-acetylcystein."，EUROPEAN JOURNAL OF CHEMISTRY，2018年12月31日，Vol.9, No.4，pp.386-393，DOI: 10.5155/eurjchem.9.4.386-393.1794
ITO, S., et al.，"Covalent binding of catechols to proteins through the sulphydryl group."，BIOCHEMICAL PHARMACOLOGY，1988年，Vol.37, No.9，pp.1707-1710，DOI: 10.1016/0006-2952(88)90432-7
ITO, S., et al.，"Tyrosinase-catalyzed oxidation of the leukoderma-inducing agent respberry ketone produces (E)-4-(3-oxo-1-butenyl)-1,2-benzoquinone: implications for melanocyte toxicity."，CHEMICAL RESEARCH IN TOXICOLOGY，2017年02月20日，Vol.30, No.3，pp.859-868，DOI: 10.1021/acs.chemrestox.7b00006
MANINI, P., et al.，"A reactive ortho-quinone genarated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity."，CHEMICAL RESEARCH IN TOXICOLOGY，2009年07月17日，Vol.22, No.8，pp.1398-1405，DOI: 10.1021/tx900018q
MAZA, J.C., et al.，"Enzymatic modification of N-terminal proline residues using phenol derivatives."，JOURNAL OF THE AMERICAN CHEMICAL SOCIETY，2019年02月06日，Vol.141, No.9，pp.385-3892，DOI: 10.1021/jacs.8b10845

Also Published As

Publication number Publication date
EP3941927A4 (en) 2023-07-19
CA3134423A1 (en) 2020-10-01
US20220153779A1 (en) 2022-05-19
KR20220003506A (ko) 2022-01-10
AU2020247788A1 (en) 2021-10-14
CN121517490A (zh) 2026-02-13
CN113891893A (zh) 2022-01-04
JP2025029024A (ja) 2025-03-05
JP2022527247A (ja) 2022-06-01
WO2020197934A1 (en) 2020-10-01
EP3941927A1 (en) 2022-01-26
US20260015381A1 (en) 2026-01-15

Similar Documents

Publication Publication Date Title
JP7598329B2 (ja) 標的分子を修飾するための組成物及び方法
AU2018214147B2 (en) Modified Antibody Compositions, Methods of Making and Using Thereof
US11028185B2 (en) Using sortases to install click chemistry handles for protein ligation
JP2023551072A (ja) Ｒｎａおよびｄｎａ修飾の多重プロファイリング
US20220010337A1 (en) Targeted active gene editing agent and methods of use
JP2014525904A5 (https=)
JP7832926B2 (ja) 制約され、条件付きで活性化された結合タンパク質
WO2013155526A2 (en) Sortase- modified vhh domains and uses thereof
US20220002695A1 (en) Targeted active gene editing agent and methods of use
WO2021062201A1 (en) Compositions and methods for nucleoprotein targeting and expression
WO2020236521A1 (en) Traceless linker and methods of use thereof
US10591481B2 (en) Methods of measuring factor D activity and potency of factor D inhibitors
US20230303709A1 (en) Antibody Derivatives with Conditionally Enabled Effector Function
Lopez et al. Epitope‐specific affinity maturation improved stability of potent protease inhibitory antibodies
AU2024340257A1 (en) Polypeptide conjugation compositions and methods of use
WO2025059190A2 (en) Polypeptide conjugation compositions and methods of use
WO2015183986A1 (en) Methods for selecting evolved transpeptidases and use thereof for creating protein conjugates
WO2025129098A1 (en) Tyrosinase-based conjugate compositions and methods of use
WO2025128586A1 (en) Traceless linker and methods of use thereof
Huhtinen ADVANCING ANTIBODY ENGINEERING
HK1197554B (en) Using sortases to install click chemistry handles for protein ligation
HK1197554A (en) Using sortases to install click chemistry handles for protein ligation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241129

R150 Certificate of patent or registration of utility model

Ref document number: 7598329

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150